kura
oncology
announces
preliminary
data
menin
inhibitor
accepted
oral
presentation
ash
san
diego
globe
newswire
kura
oncology
nasdaq
kura
biopharmaceutical
company
focused
development
precision
medicines
treatment
cancer
today
announced
abstract
reporting
preliminary
data
ongoing
clinical
trial
company
oral
potent
selective
menin
inhibitor
accepted
oral
presentation
american
society
hematology
ash
annual
meeting
exposition
following
abstract
posted
ash
website
et
november
updated
data
presented
meeting
title
preliminary
data
phase
first
human
study
mll
inhibitor
patients
relapsed
refractory
acute
myeloid
leukemia
publication
number
session
name
acute
myeloid
leukemia
novel
therapy
excluding
transplantation
novel
promising
therapies
relapsed
refractory
aml
session
date
saturday
december
session
time
presentation
time
kura
oncology
menin
inhibitor
trial
phase
study
determine
safety
tolerability
recommended
phase
dose
patients
refractory
relapsed
acute
myeloid
leukemia
aml
planned
expansion
phase
specific
genetic
subgroups
including
mutant
aml
rearranged
aml
expected
evaluate
activity
tolerability
additional
information
phase
study
found
oral
investigational
drug
candidate
novel
compound
targeting
mll
interaction
treatment
genetically
defined
aml
patients
high
unmet
need
preclinical
models
inhibits
mll
protein
complex
downstream
effects
expression
received
orphan
drug
designation
food
drug
administration
treatment
aml
kura
oncology
kura
oncology
biopharmaceutical
company
committed
realizing
promise
precision
medicines
treatment
cancer
company
pipeline
consists
two
wholly
owned
small
molecule
drug
candidates
target
cancer
signaling
pathways
strong
scientific
clinical
rationale
improve
outcomes
identifying
patients
likely
benefit
treatment
kura
advanced
drug
candidate
tipifarnib
potent
selective
orally
bioavailable
farnesyl
transferase
inhibitor
currently
trial
patients
recurrent
metastatic
hras
mutant
head
neck
squamous
cell
carcinoma
company
pipeline
also
highlighted
potent
selective
menin
inhibitor
currently
phase
clinical
trial
patients
relapsed
refractory
acute
myeloid
leukemia
additional
information
kura
please
visit
company
website
contacts
company
pete
de
spain
vice
president
investor
relations
corporate
communications
pete
investors
robert
uhl
managing
director
westwicke
partners
llc
media
jason
spark
managing
director
canale
communications
jason
